Terms: = Pancreatic cancer AND BRCA1, BRCAI, 672, ENSG00000012048, IRIS, BRCC1, RNF53, PSCP AND Prognosis
59 results:
1. Frizzled class receptor 5 contributes to ovarian cancer chemoresistance through aldehyde dehydrogenase 1A1.
Xia Y; Wang S; Sun Y; Wang W; Chang S; Zhang Z; Zhao C
Cell Commun Signal; 2024 Mar; 22(1):194. PubMed ID: 38539211
[TBL] [Abstract] [Full Text] [Related]
2. pancreatic cancer biomarkers: A pathway to advance in personalized treatment selection.
Brozos-Vázquez E; Toledano-Fonseca M; Costa-Fraga N; García-Ortiz MV; Díaz-Lagares Á; Rodríguez-Ariza A; Aranda E; López-López R
Cancer Treat Rev; 2024 Apr; 125():102719. PubMed ID: 38490088
[TBL] [Abstract] [Full Text] [Related]
3. Comprehensive review of pancreatic acinar cell carcinoma: epidemiology, diagnosis, molecular features and treatment.
Ikezawa K; Urabe M; Kai Y; Takada R; Akita H; Nagata S; Ohkawa K
Jpn J Clin Oncol; 2024 Mar; 54(3):271-281. PubMed ID: 38109477
[TBL] [Abstract] [Full Text] [Related]
4. High intramuscular adipose tissue content associated with prognosis and postoperative complications of cancers.
Liu R; Qiu Z; Zhang L; Ma W; Zi L; Wang K; Kuang T; Zhao K; Wang W
J Cachexia Sarcopenia Muscle; 2023 Dec; 14(6):2509-2519. PubMed ID: 37990969
[TBL] [Abstract] [Full Text] [Related]
5. Multimodal treatment with curative intent in a germline BRCA2 mutant metastatic ampullary adenocarcinoma: a case report.
Mauri G; Gori V; Patelli G; Roazzi L; Rizzetto F; De Carlis L; Mariani A; Cavallari U; Prada E; Cipani T; Aquilano MC; Bonoldi E; Vanzulli A; Siena S; Sartore-Bianchi A
World J Surg Oncol; 2023 Mar; 21(1):118. PubMed ID: 36998040
[TBL] [Abstract] [Full Text] [Related]
6. A case of unresectable intrahepatic cholangiocarcinoma with a germline brca1 mutation.
Yamashita Y; Ishii Y; Serikawa M; Okamoto W; Tsuboi T; Tatsukawa Y; Nakamura S; Hirano T; Ikemoto J; Oka S
Clin J Gastroenterol; 2023 Jun; 16(3):470-475. PubMed ID: 36806982
[TBL] [Abstract] [Full Text] [Related]
7. Prognostic and predictive value of tumoral DNA damage repair protein expression in patients with resected pancreatic cancer.
Ceylan F; Guven DC; Taban H; Aktepe O; Sahin TK; Kilickap S; Turker A; Hamaloglu E; Karakoc D; Isik A; Akyol A; Yalcin S; Dizdar O
Clin Res Hepatol Gastroenterol; 2023 Mar; 47(3):102091. PubMed ID: 36738855
[TBL] [Abstract] [Full Text] [Related]
8. Comparison of MRI and CT-based radiomics for preoperative prediction of lymph node metastasis in pancreatic ductal adenocarcinoma.
Zeng P; Qu C; Liu J; Cui J; Liu X; Xiu D; Yuan H
Acta Radiol; 2023 Jul; 64(7):2221-2228. PubMed ID: 36474439
[TBL] [Abstract] [Full Text] [Related]
9. Are targeted therapies or immunotherapies effective in metastatic pancreatic adenocarcinoma?
Rémond MS; Pellat A; Brezault C; Dhooge M; Coriat R
ESMO Open; 2022 Dec; 7(6):100638. PubMed ID: 36399952
[TBL] [Abstract] [Full Text] [Related]
10. Evolutionary Trajectories of Primary and Metastatic pancreatic Neuroendocrine Tumors Based on Genomic Variations.
Xu M; Yan J; Hu B; Wu C; Gu H; Qi Z; Chen T; Yang W; Zheng Y; Dong H; Sheng W; Long J
Genes (Basel); 2022 Sep; 13(9):. PubMed ID: 36140756
[TBL] [Abstract] [Full Text] [Related]
11. [Treatment of metastatic pancreatic cancer].
Heinemann V; Boeck S; Westphalen CB
Inn Med (Heidelb); 2022 Aug; 63(8):851-862. PubMed ID: 35925070
[TBL] [Abstract] [Full Text] [Related]
12. Pan-cancer analysis of the prognostic and immunological role of brca1-associated protein 1 gene (BAP1): Friend or foe?
Wang T; Zhu T; Zhang Y; Bai J; Xue Y; Xu G; Lu L; Peng Q
Gene; 2022 Oct; 840():146765. PubMed ID: 35905855
[TBL] [Abstract] [Full Text] [Related]
13. Leptomeningeal disease in BRIP1-mutated pancreatic adenocarcinoma.
Yim E; Leung D
BMJ Case Rep; 2022 Jun; 15(6):. PubMed ID: 35675963
[TBL] [Abstract] [Full Text] [Related]
14. Development and validation of a prognostic nomogram for gallbladder cancer patients after surgery.
Xu X; He M; Wang H; Zhan M; Yang L
BMC Gastroenterol; 2022 Apr; 22(1):200. PubMed ID: 35448976
[TBL] [Abstract] [Full Text] [Related]
15. Epidemiology and geographic distribution of brca1-2 and DNA Damage response genes pathogenic variants in pancreatic ductal adenocarcinoma patients.
Macchini M; Centonze F; Peretti U; Orsi G; Militello AM; Valente MM; Cascinu S; Reni M
Cancer Treat Rev; 2022 Mar; 104():102357. PubMed ID: 35184001
[TBL] [Abstract] [Full Text] [Related]
16. Analysis of a novel immune checkpoint, Siglec-15, in pancreatic ductal adenocarcinoma.
Chen X; Mo S; Zhang Y; Ma H; Lu Z; Yu S; Chen J
J Pathol Clin Res; 2022 May; 8(3):268-278. PubMed ID: 35083884
[TBL] [Abstract] [Full Text] [Related]
17. PD-L1 and PD-L2 expression in pancreatic ductal adenocarcinoma and their correlation with immune infiltrates and DNA damage response molecules.
Zhang Y; Chen X; Mo S; Ma H; Lu Z; Yu S; Chen J
J Pathol Clin Res; 2022 May; 8(3):257-267. PubMed ID: 35037417
[TBL] [Abstract] [Full Text] [Related]
18. Development of a Gene Risk Signature for Patients of pancreatic cancer.
Liu T; Chen L; Gao G; Liang X; Peng J; Zheng M; Li J; Ye Y; Shao C
J Healthc Eng; 2022; 2022():4136825. PubMed ID: 35035831
[TBL] [Abstract] [Full Text] [Related]
19. Systemic Therapy for Metastatic pancreatic cancer.
Ettrich TJ; Seufferlein T
Curr Treat Options Oncol; 2021 Oct; 22(11):106. PubMed ID: 34665339
[TBL] [Abstract] [Full Text] [Related]
20. Hereditary pancreatic cancer.
Abe K; Kitago M; Kitagawa Y; Hirasawa A
Int J Clin Oncol; 2021 Oct; 26(10):1784-1792. PubMed ID: 34476650
[TBL] [Abstract] [Full Text] [Related]
[Next]
